RxDoctor Payments Data

Pansy Uberoi, MD

Urogynecology and Reconstructive Pelvic Surgery · Jbsa Lackland, TXNPI 1144665886

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,285 of the $8,414 with a category attached, or 86.6%. 10 manufacturers reported payments, led by Medtronic at 49.2% of the total. Reporting peaked in 2024 at $2,466 and has fallen 93.6% since, to $157 in 2025.

$8,414in general payments, 2019–2025

Across 101 payments — averaging $83.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Coloplast$2K
  • Boston Scientific$950
  • Axonics, Inc.$637
  • Cook Medical LLC$105
  • Convatec Inc.$104
  • plus $285 from 4 others
$355in research payments, 2019–2025

Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$355

What the payments were for

  • Travel & lodging$1,12913%
  • Food & beverage$7,28587%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)59$4,143
Coloplast20$2,190
Boston Scientific8$950
Axonics, Inc.7$637
Cook Medical LLC1$105
Convatec Inc.1$104
Neotract Inc.1$92
Bluewind Medical1$86
AbbVie(2 entities)2$84
Tolmar, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,414 in reported general payments places this provider in the 65th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.

See all urogynecology and reconstructive pelvic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$16,765
Medicare patients
29
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol18$1,434

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Jbsa Lackland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →